Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $34.85 | Total: $174.25 |
| 1 | 10 | $29.52 | Total: $295.20 |
| 1 | 25 | $25.01 | Total: $625.25 |
| 1 | 50 | $21.32 | Total: $1,066.00 |
| 1 | 100 | $18.45 | Total: $1,845.00 |
Overview
Talmapimod (SCIO-469) is a selective, orally active, ATP-competitive p38? inhibitor with IC50 values of 9 nM for p38? and 90 nM for p38?. Talmapimod exhibits at least 2000-fold selectivity over a panel of 20 kinases, including other MAPKs.
Chemical Properties
| Molecular Formula | C27H30ClFN4O3 |
| Molecular Weight | 513 |
| CAS Numbers | 309913-83-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C |
Storage and Handling
0C Short Term, -20C Long Term
References
Hideshima T et al. p38 MAPK inhibition enhances PS-341 [bortezomib]-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18, 23[54], 8766-76.